The Official Hagmann Report – Autism Stole His Words – God Gave Him His Voice – Tahni Cullen on The Hagmann Report
An incredible story about Tahni’s son, Josiah, who suddenly and miraculously broke through the chains of Autism in a manner you must hear to believe. From the clinical to the inexplicable, this story will leave you both informed and inspired.
D’Souza RM, D’Souza R.
Author information
National Centre for Epidemiology and Population Health, The Australian National University, Canberra, ACT, Australia, 0200. rennie.dsouza@anu.edu.au
Update in
Vitamin A for treating measles in children. [Cochrane Database Syst Rev. 2005]
Abstract
BACKGROUND:
Measles is a leading cause of childhood morbidity and mortality. Vitamin A deficiency is a recognised risk factor for severe measles. The World Health Organization (WHO) recommends administration of an oral dose of 200,000 IU (or 100,000 IU in infants) of vitamin A per day for two days to children with measles in areas where vitamin A deficiency may be present.
OBJECTIVES:
The purpose of this review is to determine whether vitamin A when commenced after measles has been diagnosed, is beneficial in preventing mortality, pneumonia and other complications in children.
SEARCH STRATEGY:
MEDLINE and the Cochrane Library, Issue 4, 1999 were searched.
SELECTION CRITERIA:
Only randomized controlled trials in which children with measles were given vitamin A or placebo along with standard treatment were considered.
DATA COLLECTION AND ANALYSIS:
Studies were assessed independently by two reviewers. The analysis of dichotomous outcomes was done using the StatXact software package. Sub-group analyses were done for dose, formulation, age, hospitalisation and pneumonia specific mortality. Weighted mean difference with 95% CI were calculated for continuous outcomes.
MAIN RESULTS:
The relative risks (RR) and 95% Confidence Intervals (CI) are based on the estimates from the StatXact software package. There was no significant reduction in mortality in the vitamin A group when all the studies were pooled together (RR 0.60; 95% CI 0.32 to 1.12)(StatXact estimate). There was a 64% reduction in the risk of mortality in children who were given two doses of 200,000 IU of vitamin A (RR=0.36; 95% CI 0.14 to 0.82) as compared to placebo. Two doses of water based vitamin A were associated with a 81% reduction in risk of mortality (RR=0.19; 95% CI 0.02 to 0.85) as compared to 48% seen in two doses of oil based preparation (RR=0.52; 95% CI 0.16 to 1.40). Two doses of oil and water based vitamin A were associated with a 82% reduction in the risk of mortality in children under the age of 2 years (RR=0.18; 95% CI 0.03 to 0.61) and a 67% reduction in the risk of pneumonia specific mortality (RR=0.33; 95% CI 0.08 to 0.92). There was no evidence that vitamin A in a single dose of 200,000 IU was associated with a reduced risk of mortality among children with measles (RR=0.77; 95% CI 0.34 to 1.78). Sub-groups like age, dose, formulation, hospitalisation and case fatality in the study area were highly correlated and there were not enough studies to separate out the individual effects of these factors. There was a 47% reduction in the incidence of croup (RR=0.53; 95% CI 0.29 to 0.89), while there was no significant reduction in the incidence of pneumonia (RR=0.92; 95% CI 0.69 to 1.22) or of diarrhoea (RR=0.80; 95% CI 0.27 to 2.34). Duration of diarrhoea was measured in days and there was a reduction in its duration of almost two days WMD -1.92, 95% CI -3.40 to -0.44. Only one study evaluated otitis media and found a 74% reduction in its incidence (RR=0.26, 95% CI, 0.05 to 0.92). We did not find evidence that a single dose of 200,000 IU of vitamin A per day, given in oil-based formulation in areas with low case fatality, was associated with reduced mortality among children with measles. However, there was evidence that the same dose given for two days was associated with a reduced risk of overall mortality and pneumonia specific mortality.
REVIEWER’S CONCLUSIONS:
Although we did not find evidence that a single dose of 200,000 IU of vitamin A per day was associated with reduced mortality among children with measles, there was evidence that the same dose given for two days was associated with a reduced risk of overall mortality and pneumonia specific mortality. The effect was greater in children under the age of two years. There were no trials that compared a single dose with two doses, although the precision of the estimates of trials that used a single dose were similar to the trials that used two doses.
US National Library of Medicine
National Institutes of Health – Sep 1995
P A Rota, A S Khan, E Durigon, T Yuran, Y S Villamarzo, and W J Bellini
Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
ABSTRACT
Analysis of urine specimens by using reverse transcriptase-PCR was evaluated as a rapid assay to identify individuals infected with measles virus. For the study, daily urine samples were obtained from either 15-month-old children or young adults following measles immunization. Overall, measles virus RNA was detected in 10 of 12 children during the 2-week sampling period. In some cases, measles virus RNA was detected as early as 1 day or as late as 14 days after vaccination. Measles virus RNA was also detected in the urine samples from all four of the young adults between 1 and 13 days after vaccination. This assay will enable continued studies of the shedding and transmission of measles virus and, it is hoped, will provide a rapid means to identify measles infection, especially in mild or asymptomatic cases
Unul din vaccinurile “cruciale” din schemele recomandate pe intreg mapamondul este vaccinul anti hepatita B.
Diagnosticul de asa-zisa “hepatita B” este de fapt descrierea simptomelor: hepatitis = inflamarea ficatului. Ca atare, hepatita B nu are cum sa fie o boala, ci este o descriere de simptome care indica o afectiune grava a ficatului si care nu este cauzata de niciun virus, deoarece nu exista in intreaga literatura medicala vreo sursa care sa demonstreze faptul ca vreun virus ar cauza hepatita B.
In schimb, exista multe studii si lucrari stiintifice despre modul cum in mod special vaccinul antihepatic distruge ficatul.In conformitate cu prospectul vaccinului antihepatic, iata ce reactii adverse au fost raportate dupa administrarea vaccinului antihepatic B:
Herpes zoster, meningita, trombocitopenie, reactie anafilactoida, anafilaxa; sindromul hipersensitivitatii, inclusiv artralgie/artrita (de obicei temporara), febra, reactii dermatologice gen urticarie, eritem multiform, echimoze, erythema nodosum, apoi encefalita, encefalopatie, migrene, scleroza multipla, nevrita, neuropatie inclusiv hipoestezie faciala, parestezie, sindromul Guillain-Barré, paralizie Bell, nevrita optica, paralizii, pareze, convulsii, sincope, mielita transversa, conjunctivita, keratita, tulburari vizuale, dureri de urechi, tinnitus, vertigo, palpitatii, tahicardie, vasculita, apnee, spasme bronhice inclusiv simptome astmatice, dispepsie, alopecie, angioedema, eczeme, eriteme multiforme inclusiv sindromul Stevens-Johnson, erythema nodosum, lichen planus, purpura, artrita, slabiciuni musculare.
VAXXED TV – Their Names Will Never Be On This Bus
I Gave The Shot
Two Doses of MMR
Force Vaccinated By Her Father
MMR During Pregnancy
I’m Done.
Fully Recovered From Autism
Flu Shot Killed Grandpa
He Brought Me a List with 17 Empty Spaces
You Have an Obligation to Your Children to Research It
1 Moreover, brethren, I declare unto you the gospel which I preached unto you, which also ye have received, and wherein ye stand;
2 by which also ye are saved, if ye keep in memory what I preached unto you, unless ye have believed in vain.
3 For I delivered unto you first of all that which I also received, how that Christ died for our sins according to the scriptures;
4 and that he was buried, and that he rose again the third day according to the scriptures:
Hebrews 6 Authorized (King James) Version (AKJV)
1 Therefore leaving the principles of the doctrine of Christ, let us go on unto perfection; not laying again the foundation of repentance from dead works, and of faith toward God,
2 of the doctrine of baptisms, and of laying on of hands, and of resurrection of the dead, and of eternal judgment.
3 And this will we do, if God permit.
4 For it is impossible for those who were once enlightened, and have tasted of the heavenly gift, and were made partakers of the Holy Ghost,
5 and have tasted the good word of God, and the powers of the world to come,
6 if they shall fall away, to renew them again unto repentance; seeing they crucify to themselves the Son of God afresh, and put him to an open shame.
7 For the earth which drinketh in the rain that cometh oft upon it, and bringeth forth herbs meet for them by whom it is dressed, receiveth blessing from God:
8 but that which beareth thorns and briers is rejected, and is nigh unto cursing; whose end is to be burned.
1 Who hath believed our report? and to whom is the arm of the Lord revealed?
2 For he shall grow up before him as a tender plant,and as a root out of a dry ground:he hath no form nor comeliness;and when we shall see him,there is no beauty that we should desire him.
3 He is despised and rejected of men;a man of sorrows, and acquainted with grief:and we hid as it were our faces from him;he was despised, and we esteemed him not.
4 Surely he hath borne our griefs,and carried our sorrows:yet we did esteem him stricken,smitten of God, and afflicted.
5 But he was wounded for our transgressions,he was bruised for our iniquities:the chastisement of our peace was upon him;and with his stripes we are healed.
6 All we like sheep have gone astray;we have turned every one to his own way;and the Lord hath laid on him the iniquity of us all.
7 He was oppressed, and he was afflicted,yet he opened not his mouth:he is brought as a lamb to the slaughter,and as a sheep before her shearers is dumb,so he openeth not his mouth.
8 He was taken from prison and from judgment:and who shall declare his generation? for he was cut off out of the land of the living:for the transgression of my people was he stricken.
9 And he made his grave with the wicked,and with the rich in his death;because he had done no violence,neither was any deceit in his mouth.
10 Yet it pleased the Lord to bruise him;he hath put him to grief:when thou shalt make his soul an offering for sin,he shall see his seed, he shall prolong his days,and the pleasure of the Lord shall prosper in his hand.
11 He shall see of the travail of his soul, and shall be satisfied:by his knowledge shall my righteous servant justify many;for he shall bear their iniquities.
12 Therefore will I divide him a portion with the great,and he shall divide the spoil with the strong;because he hath poured out his soul unto death:and he was numbered with the transgressors;and he bare the sin of many,and made intercession for the transgressors.
Duane L. Pierson,1 Satish K. Mehta,2 Don Gilden,corresponding author4,5 Randall J. Cohrs,4 Maria A. Nagel,4 D. Scott Schmid,6 and Stephen K. Tyring3
1 Space Life Sciences, NASA, Lyndon B. Johnson Space Center
2 Enterprise Advisory Services, Inc
3 University of Texas Health Science Center, Houston, Texas
4 Department of Neurology
5 Microbiology, University of Colorado School of Medicine, Aurora
6 National VZV Laboratory, Centers for Disease Control and Prevention, Atlanta, Georgia
Correspondence: Don Gilden, MD, Department of Neurology, University of Colorado School of Medicine, 12700 E 19th Ave, Box B182, Aurora, CO 80045 (ude.revnedcu@nedlig.nod).
Abstract
Analysis of 36 individuals over age 60 years who were immunized with Zostavax revealed varicella zoster virus (VZV) DNA in swabs of skin inoculation sites obtained immediately after immunization in 18 (50%) of 36 subjects (copy number per nanogram of total DNA, 28 to 2.1 × 106) and in saliva collected over 28 days in 21 (58%) of 36 subjects (copy number, 20 to 248). Genotypic analysis of DNA extracted from 9 random saliva samples identified vaccine virus in all instances. In some immunized individuals over age 60, vaccine virus DNA is shed in saliva up to 4 weeks.
Varicella zoster virus (VZV) is a neurotropic alphaherpesvirus. Primary infection usually causes varicella (chicken pox) in children. Airborne VZV enters the nasopharynx and replicates in tonsillar T cells followed by viremia and skin lesions [1, 2]. After primary infection, VZV becomes latent in neurons of cranial nerve ganglia, dorsal root ganglia, and autonomic ganglia along the entire neuraxis. Decades later, VZV reactivates in elderly and immunocompromised individuals to produce zoster (shingles), a syndrome characterized by pain and a vesicular rash on an erythematous base in 1–3 dermatomes. Zoster is common, with ∼1,000,000 cases annually in the United States. Importantly, zoster is often followed by chronic pain (postherpetic neuralgia [PHN]) as well as by meningoencephalitis, cerebellitis, cranial nerve palsies, vasculopathy, myelopathy, and multiple inflammatory diseases of the eye [3].
To prevent zoster and its attendant neurological complications, Zostavax vaccine (Merck) was approved by the Food and Drug Administration for use in individuals at least 60 years of age. Over a 3-year period, Zostavax effectively reduced the risk of zoster by 51% and PHN by 66% in nearly 20,000 healthy adults age 60 years or older [4]. Zostavax contains live attenuated VZV, and the package insert warns newly vaccinated individuals to avoid contact for an unspecified time with newborn infants, immunosuppressed individuals, and pregnant women who have not had chicken pox or have not been immunized for chicken pox. Because VZV DNA is present in saliva of zoster patients for at least 2 weeks [5] and VZV in saliva can also be infectious [6], we examined the inoculation site and saliva of Zostavax-vaccinated subjects for the presence of VZV DNA for 4 weeks after immunization.
US National Library of Medicine
National Institutes of Health – 1980
SIR,-The recommendations and medicolegal implications of smallpox vaccination have been discussed in these columns on several occasions
(11 October 1980, p 1004; 25 October, pp 1141 and 1142).
Although vaccination for the public is no longer necessary it is worth noting, as Minerva pointed out (4 April, p 1163), that it continues to be offered to the British Army (both regular and reserve). The risk of transmission of vaccinia by recently vaccinated soldiers to their close and immediate susceptible contacts therefore is likely to increase. This has been illustrated in the following case. A 23-year-old Scottish housewife was referred to the gynaecology department of this hospital on 17 December from the local family planning clinic for confirmation of diagnosis of presumed genital herpes simplex infection. The patient had developed painful itchy lesions on the vulva one week previously and she had also noticed similar lesions on her left loin and ear lobe. On examination she had large moist umbilicated vesicles on the vulva as well as on her left hip and left ear lobe. A clinical diagnosis of vaccinia was confirmed at the regional virus laboratory, Ruchill Hospital, by electron microscopy, and vaccinia virus was isolated in cell culture. These lesions rapidly regress,.d and healed with local application of betadine paint. The history of contact with a vaccinated person was not volunteered; but on close questioning it was revealed that the patient’s husband, who had joined the Royal Air Force, had been vaccinated three weeks previously and had been home at weekends. The patient herself had not been vaccinated in the past. In 1980, of six reported incidents of contact vaccinia received by the Communicable Disease Surveillance Centre,1 one was almost identical to our own case: a young woman whose soldier husband had been vaccinated three weeks previously developed genital vaccinia. Another case was in a soldier who had taken part in a boxing match and may have been infected by a colleague. The immediate and obvious question that arises is whether vaccination in the armed Forces is justifiable when there is no valid medical reason for it, and it is no longer necessary for international travel (except to Chad and democratic Kampuchea). The policy of smallpox vaccination has been discussed in a recent editorial of the Jrournal of the Royal Army Medical Corps2 and the main argument for vaccination seems to be to protect the Forces against the possible use of smallpox virus by an enemy as an agent of biological warfare. If the vaccination of the army personnel should continue because of this unlikely but perfectly feasible threat of germ warfare, one can only endorse the view that “Continued education of service personnel and their contacts about the risk and its prevention is now, therefore, even more essential than before.”3 Otherwise we might see more cases of genital vaccinia in women transmitted from recently vaccinated young, healthy, virile British soldiers.
US National Library of Medicine
National Institutes of Health – Feb 2012
Wertheimer ER, Olive DS, Brundage JF, Clark LL.
Author information
Armed Forces Health Surveillance Center, 11800 Tech Road, Suite 220, Silver Spring, MD 20904, USA. ellen.wertheimer@us.army.mil
Abstract
Since 2002, approximately 40,000 US civilians and 2.1 million military personnel have been vaccinated against smallpox. The vaccine contains live vaccinia virus that can be transferred through physical contact. This report summarizes numbers, rates, and characteristics of contact vaccinia cases that presented between December 2002 and March 2011. Cases were identified from reports in adverse event reporting systems and peer-reviewed literature. One hundred fifteen cases of vaccinia transmission through contact were identified (5.4 per 100,000 vaccinees); 52 reports (45%) noted laboratory confirmation. Three-quarters of vaccinees, but fewer than 8% of contact vaccinia cases, were described as military members. Most cases were household or intimate contacts (n=86, 75%) or wrestling partners (n=18, 16%) of vaccinees. Nearly all cases manifested mild, local skin reactions; of 14 hospitalized cases, one was life-threatening. Vaccinia transmission from vaccinees is relatively infrequent. Continued attention to both vaccinee education and screening for contraindications to vaccination is appropriate.
VAXXED TV – Lunchtime in Australia
Channel 7 news Australia
Fake News on The Radio!
MMR Gave my son autism
My son is vaccine injured
Vaccines injured me and my daughter
Q&A Brisbane, Australia
Sunshine Coast people’s study – Vaccinated vs. Unvaccinated
1 Corinthians 15 Authorized (King James) Version (AKJV)
1 Moreover, brethren, I declare unto you the gospel which I preached unto you, which also ye have received, and wherein ye stand;
2 by which also ye are saved, if ye keep in memory what I preached unto you, unless ye have believed in vain.
3 For I delivered unto you first of all that which I also received, how that Christ died for our sins according to the scriptures;
4 and that he was buried, and that he rose again the third day according to the scriptures:
Hebrews 6 Authorized (King James) Version (AKJV)
1 Therefore leaving the principles of the doctrine of Christ, let us go on unto perfection; not laying again the foundation of repentance from dead works, and of faith toward God,
2 of the doctrine of baptisms, and of laying on of hands, and of resurrection of the dead, and of eternal judgment.
3 And this will we do, if God permit.
4 For it is impossible for those who were once enlightened, and have tasted of the heavenly gift, and were made partakers of the Holy Ghost,
5 and have tasted the good word of God, and the powers of the world to come,
6 if they shall fall away, to renew them again unto repentance; seeing they crucify to themselves the Son of God afresh, and put him to an open shame.
7 For the earth which drinketh in the rain that cometh oft upon it, and bringeth forth herbs meet for them by whom it is dressed, receiveth blessing from God:
8 but that which beareth thorns and briers is rejected, and is nigh unto cursing; whose end is to be burned.
1 Who hath believed our report? and to whom is the arm of the Lord revealed?
2 For he shall grow up before him as a tender plant,and as a root out of a dry ground:he hath no form nor comeliness;and when we shall see him,there is no beauty that we should desire him.
3 He is despised and rejected of men;a man of sorrows, and acquainted with grief:and we hid as it were our faces from him;he was despised, and we esteemed him not.
4 Surely he hath borne our griefs,and carried our sorrows:yet we did esteem him stricken,smitten of God, and afflicted.
5 But he was wounded for our transgressions,he was bruised for our iniquities:the chastisement of our peace was upon him;and with his stripes we are healed.
6 All we like sheep have gone astray;we have turned every one to his own way;and the Lord hath laid on him the iniquity of us all.
7 He was oppressed, and he was afflicted,yet he opened not his mouth:he is brought as a lamb to the slaughter,and as a sheep before her shearers is dumb,so he openeth not his mouth.
8 He was taken from prison and from judgment:and who shall declare his generation? for he was cut off out of the land of the living:for the transgression of my people was he stricken.
9 And he made his grave with the wicked,and with the rich in his death;because he had done no violence,neither was any deceit in his mouth.
10 Yet it pleased the Lord to bruise him;he hath put him to grief:when thou shalt make his soul an offering for sin,he shall see his seed, he shall prolong his days,and the pleasure of the Lord shall prosper in his hand.
11 He shall see of the travail of his soul, and shall be satisfied:by his knowledge shall my righteous servant justify many;for he shall bear their iniquities.
12 Therefore will I divide him a portion with the great,and he shall divide the spoil with the strong;because he hath poured out his soul unto death:and he was numbered with the transgressors;and he bare the sin of many,and made intercession for the transgressors.
Elizabeth Mumper, MD, FAAP*
2919 Confederate Avenue, Lynchburg, VA
Emerging research suggests that the timing of environmental factors in the presence of genetic predispositions has influenced the increase in autism spectrum disorders over the past several decades. A review of the medical literature suggests that autism may be impacted by environmental toxicants, breastfeeding duration, gut flora composition, nutritional status, acetaminophen use, vaccine practices and use of antibiotics and/or frequency of infections. The author reports her retrospective clinical research in a general pediatric practice (Advocates for Children), which shows a modest trend toward lower prevalence of autism than her previous pediatric practice or recent CDC data. Out of 294 general pediatrics patients followed since 2005 there were zero new cases of autism (p value 0.014). Given the prevalence of autism for that cohort of 1 in 50 children in the United States, it is important to consider implementing strategies in primary care practice that could potentially modify environmental factors or affect the timing of environmental triggers contributing to autism.
National Library of Medicine
National Institutes of Health – Jul 2009
Author information
Graham E. Ewing
Montague Healthcare, Mulberry House, 6 Vine Farm Close, Cotgrave, Nottingham NG12 3TU, United Kingdom
Abstract
There is a compelling argument that the occurrence of regressive autism is attributable to genetic and chromosomal abnormalities, arising from the overuse of vaccines, which subsequently affects the stability and function of the autonomic nervous system and physiological systems. That sense perception is linked to the autonomic nervous system and the function of the physiological systems enables us to examine the significance of autistic symptoms from a systemic perspective. Failure of the excretory system influences elimination of heavy metals and facilitates their accumulation and subsequent manifestation as neurotoxins: the long-term consequences of which would lead to neurodegeneration, cognitive and developmental problems. It may also influence regulation of neural hyperthermia. This article explores the issues and concludes that sensory dysfunction and systemic failure, manifested as autism, is the inevitable consequence arising from subtle DNA alteration and consequently from the overuse of vaccines.
Case 3. Richard M. was referred to the Johns Hopkins Hospital on February 5, 1941, at 3 years, 3 months of age, with the complaint of deafness because he didnot talk and did not respond to questions.
Following smallpox vaccination at 12 months, he had an attack of diarrhea and fever, from which he recovered in somewhat less than a week
In september, 1940, the mother, in commenting on Richard’s failure to talk, remarked in her notes: I can’t be sure just when he stopped the imitation of wordssounds. It seems that he has gone backward mentally gradually for the last two years.
Richard M
November 1937 – Born
November 1938 – vaccinated with Smallpox vaccine
September 1940 – Mother reports developmental regression beginning approximately two years previously
February 1941 – Referred to Hopkins for evaluation
1943 – Becomes the third child to be described as autistic by Leo Kanner in his disorder defining paper, the first paper published on autism
VAXXED TV – Hib Vaccination: The Bigger Picture #PrayBig
1 Corinthians 15 Authorized (King James) Version (AKJV)
1 Moreover, brethren, I declare unto you the gospel which I preached unto you, which also ye have received, and wherein ye stand;
2 by which also ye are saved, if ye keep in memory what I preached unto you, unless ye have believed in vain.
3 For I delivered unto you first of all that which I also received, how that Christ died for our sins according to the scriptures;
4 and that he was buried, and that he rose again the third day according to the scriptures:
Hebrews 6 Authorized (King James) Version (AKJV)
1 Therefore leaving the principles of the doctrine of Christ, let us go on unto perfection; not laying again the foundation of repentance from dead works, and of faith toward God,
2 of the doctrine of baptisms, and of laying on of hands, and of resurrection of the dead, and of eternal judgment.
3 And this will we do, if God permit.
4 For it is impossible for those who were once enlightened, and have tasted of the heavenly gift, and were made partakers of the Holy Ghost,
5 and have tasted the good word of God, and the powers of the world to come,
6 if they shall fall away, to renew them again unto repentance; seeing they crucify to themselves the Son of God afresh, and put him to an open shame.
7 For the earth which drinketh in the rain that cometh oft upon it, and bringeth forth herbs meet for them by whom it is dressed, receiveth blessing from God:
8 but that which beareth thorns and briers is rejected, and is nigh unto cursing; whose end is to be burned.
1 Who hath believed our report? and to whom is the arm of the Lord revealed?
2 For he shall grow up before him as a tender plant,and as a root out of a dry ground:he hath no form nor comeliness;and when we shall see him,there is no beauty that we should desire him.
3 He is despised and rejected of men;a man of sorrows, and acquainted with grief:and we hid as it were our faces from him;he was despised, and we esteemed him not.
4 Surely he hath borne our griefs,and carried our sorrows:yet we did esteem him stricken,smitten of God, and afflicted.
5 But he was wounded for our transgressions,he was bruised for our iniquities:the chastisement of our peace was upon him;and with his stripes we are healed.
6 All we like sheep have gone astray;we have turned every one to his own way;and the Lord hath laid on him the iniquity of us all.
7 He was oppressed, and he was afflicted,yet he opened not his mouth:he is brought as a lamb to the slaughter,and as a sheep before her shearers is dumb,so he openeth not his mouth.
8 He was taken from prison and from judgment:and who shall declare his generation? for he was cut off out of the land of the living:for the transgression of my people was he stricken.
9 And he made his grave with the wicked,and with the rich in his death;because he had done no violence,neither was any deceit in his mouth.
10 Yet it pleased the Lord to bruise him;he hath put him to grief:when thou shalt make his soul an offering for sin,he shall see his seed, he shall prolong his days,and the pleasure of the Lord shall prosper in his hand.
11 He shall see of the travail of his soul, and shall be satisfied:by his knowledge shall my righteous servant justify many;for he shall bear their iniquities.
12 Therefore will I divide him a portion with the great,and he shall divide the spoil with the strong;because he hath poured out his soul unto death:and he was numbered with the transgressors;and he bare the sin of many,and made intercession for the transgressors.
a The Birchall Centre, Lennard-Jones Laboratories, Keele University, Staffordshire, ST5 5BG, United Kingdom
b Life Sciences, Keele University, Staffordshire, ST5 5BG, United Kingdom
c Department of Clinical Neuropathology, Kings College Hospital, London, SE5 9RS, United Kingdom
Abstract
Autism spectrum disorder is a neurodevelopmental disorder of unknown aetiology. It is suggested to involve both genetic susceptibility and environmental factors including in the latter environmental toxins. Human exposure to the environmental toxin aluminium has been linked, if tentatively, to autism spectrum disorder. Herein we have used transversely heated graphite furnace atomic absorption spectrometry to measure, for the first time, the aluminium content of brain tissue from donors with a diagnosis of autism. We have also used an aluminium-selective fluor to identify aluminium in brain tissue using fluorescence microscopy. The aluminium content of brain tissue in autism was consistently high. The mean (standard deviation) aluminium content across all 5 individuals for each lobe were 3.82(5.42), 2.30(2.00), 2.79(4.05) and 3.82(5.17) μg/g dry wt. for the occipital, frontal, temporal and parietal lobes respectively. These are some of the highest values for aluminium in human brain tissue yet recorded and one has to question why, for example, the aluminium content of the occipital lobe of a 15 year old boy would be 8.74 (11.59) μg/g dry wt.? Aluminium-selective fluorescence microscopy was used to identify aluminium in brain tissue in 10 donors. While aluminium was imaged associated with neurones it appeared to be present intracellularly in microglia-like cells and other inflammatory non-neuronal cells in the meninges, vasculature, grey and white matter. The pre-eminence of intracellular aluminium associated with non-neuronal cells was a standout observation in autism brain tissue and may offer clues as to both the origin of the brain aluminium as well as a putative role in autism spectrum disorder.
US National Library of Medicine
National Institutes of Health – Oct 2012
Goldman GS, Miller NZ.
Author information
Computer Scientist, Pearblossom, CA 93553, USA. gsgoldman@roadrunner.com
Abstract
In this study, the Vaccine Adverse Event Reporting System (VAERS) database, 1990-2010, was investigated; cases that specified either hospitalization or death were identified among 38,801 reports of infants. Based on the types of vaccines reported, the actual number of vaccine doses administered, from 1 to 8, was summed for each case. Linear regression analysis of hospitalization rates as a function of (a) the number of reported vaccine doses and (b) patient age yielded a linear relationship with r(2) = 0.91 and r(2) = 0.95, respectively. The hospitalization rate increased linearly from 11.0% (107 of 969) for 2 doses to 23.5% (661 of 2817) for 8 doses and decreased linearly from 20.1% (154 of 765) for children aged <0.1 year to 10.7% (86 of 801) for children aged 0.9 year. The rate ratio (RR) of the mortality rate for 5-8 vaccine doses to 1-4 vaccine doses is 1.5 (95% confidence interval (CI), 1.4-1.7), indicating a statistically significant increase from 3.6% (95% CI, 3.2-3.9%) deaths associated with 1-4 vaccine doses to 5.5% (95% CI, 5.2-5.7%) associated with 5-8 vaccine doses. The male-to-female mortality RR was 1.4 (95% CI, 1.3-1.5). Our findings show a positive correlation between the number of vaccine doses administered and the percentage of hospitalizations and deaths. Since vaccines are given to millions of infants annually, it is imperative that health authorities have scientific data from synergistic toxicity studies on all combinations of vaccines that infants might receive. Finding ways to increase vaccine safety should be the highest priority.
The Association of American Physicians and Surgeons notes that, because of public concerns that mercury (as thimerosal) in childhood vaccines might be contributing to soaring rates of autism, this component was mostly phased out as a “precaution.” Autism rates continued to rise, prompting authorities to assert that autism is not linked to mercury in vaccines and that vaccination policies are safe and appropriate, writes Neil Z. Miller in the winter issue of the Journal of American Physicians and Surgeons.
ABSTRACT
Aluminum is a neurotoxin, yet infants and young children are repeatedly injected with aluminum adjuvants from multiple vaccines during critical periods of brain development. Numerous studies provide credible evidence that aluminum adversely affects important biological functions and may contribute to neurodegenerative and autoimmune disorders. It is impossible to predetermine which vaccinated babies will succumb to aluminum poisoning. Aluminum-free health options are needed.
PDF: http://www.jpands.org/vol21no4/miller.pdf
Study Shows Evidence of Inflammatory Cells Loaded with Aluminum Crossing the Blood-Brain Barrier and Meningeal Membranes
(November 27, 2017) Staffordshire, UK — A new study published in the Journal of Trace Elements in Medicine and Biology provides the strongest indication yet that aluminum is an etiological agent in autism spectrum disorder (ASD), according to researchers at Keele University in England.
The study used transversely heated graphite furnace atomic absorption spectrometry to measure, for the first time, the aluminum content of brain tissue from five donors who had died with diagnoses of ASD. The results showed the donors to have had some of the highest values of aluminum yet measured in human brain tissue.
The mean (standard deviation) aluminum content across all five individuals for each lobe were 3.82(5.42), 2.30(2.00), 2.79(4.05) and 3.82(5.17) mg/g dry wt. for the occipital, frontal, temporal and parietal lobes respectively. Previous measurements of 60 brains from humans not diagnosed with ASD showed an average content of 1 mg/g dry wt. of brain tissue.
“One has to wonder why aluminum in the occipital lobe of a 15-year-old boy with autism would be a value that is at least 10 times higher than what might be considered acceptable for an elderly adult?” said Christopher Exley PhD, Professor in Bioinorganic Chemistry and author of the study. Another ground-breaking study by Exley and his team, published earlier in the year, identified similarly high levels of aluminum in the brains of individuals who died of familial Alzheimer’s disease.
When it comes to the most widely used adjuvant ingredient found within vaccines, aluminum, many questions have yet to be answered, particularly when it comes to where the aluminum goes after injection, an issue known as biopersistence.
One reason this question arises is because a causative role has been established in what’s known as macrophagic myofasciitis (MMF) lesion in patients who have myalgic encephalomyelitis, or brain inflammation. Myalgia, arthralgia, chronic fatigue, cognitive dysfunction, dysautonomia, and autoimmunity have been temporally linked to aluminium adjuvant-containing vaccine administration (Gherardi and Authier, 2003; Authier et al., 2003; Exley et al., 2009; Rosenblum et al., 2011; Santiago et al., 2014; Brinth et al., 2015; Palmieri et al., 2016).
“Evidence that aluminum-coated particles phagocytozed in the injected muscle and its draining lymph nodes can disseminate within phagocytes throughout the body and slowly accumulate in the brain further suggested that alum safety should be evaluated in the long term.”
US National Library of Medicine
National Institutes of Health – Jun 2015
Eidi H – 1,2, David MO – 3, Crépeaux G – 4, Henry L – 5, Joshi V – 6, Berger MH – 7, Sennour M – 8, Cadusseau J – 9,10, Gherardi RK – 11, Curmi PA – 12.
Author information
1 Institut National de la Santé et de la Recherche Médicale (INSERM) – UMR 1204, Université Evry-Val d’Essonne, Laboratoire Structure-Activité des Biomolécules Normales et Pathologiques, Evry, France. housam.eidi@gmail.com.
2 Inserm – U955, Université Paris Est, Faculté de Médecine, Créteil, France. housam.eidi@gmail.com.
3 Institut National de la Santé et de la Recherche Médicale (INSERM) – UMR 1204, Université Evry-Val d’Essonne, Laboratoire Structure-Activité des Biomolécules Normales et Pathologiques, Evry, France. MO.David@iut.univ-evry.fr.
4 Inserm – U955, Université Paris Est, Faculté de Médecine, Créteil, France. guillemette.crepeaux@gmail.com.
5 Institut National de la Santé et de la Recherche Médicale (INSERM) – UMR 1204, Université Evry-Val d’Essonne, Laboratoire Structure-Activité des Biomolécules Normales et Pathologiques, Evry, France. laetitia.henry@wanadoo.fr.
6 Institut National de la Santé et de la Recherche Médicale (INSERM) – UMR 1204, Université Evry-Val d’Essonne, Laboratoire Structure-Activité des Biomolécules Normales et Pathologiques, Evry, France. vandana.joshi@univ-evry.fr.
7 Laboratoire Pierre-Marie Fourt, Centre des Matériaux de l’Ecole des Mines de Paris and CNRS UMR 7633, Evry, France. marie-helene.berger@mines-paristech.fr.
8 Laboratoire Pierre-Marie Fourt, Centre des Matériaux de l’Ecole des Mines de Paris and CNRS UMR 7633, Evry, France. mohamed.sennour@ensmp.fr.
9 Inserm – U955, Université Paris Est, Faculté de Médecine, Créteil, France. josette.cadusseau@inserm.fr.
10 Faculté des Sciences et Technologie UPEC, Créteil, France. josette.cadusseau@inserm.fr.
11 Inserm – U955, Université Paris Est, Faculté de Médecine, Créteil, France. romain.gherardi@hmn.aphp.fr.
12 Institut National de la Santé et de la Recherche Médicale (INSERM) – UMR 1204, Université Evry-Val d’Essonne, Laboratoire Structure-Activité des Biomolécules Normales et Pathologiques, Evry, France. pcurmi@univ-evry.fr.
Abstract
BACKGROUND:
Aluminum oxyhydroxide (alum) is a crystalline compound widely used as an immunologic adjuvant of vaccines. Concerns linked to alum particles have emerged following recognition of their causative role in the so-called macrophagic myofasciitis (MMF) lesion in patients with myalgic encephalomyelitis, revealing an unexpectedly long-lasting biopersistence of alum within immune cells and a fundamental misconception of its biodisposition. Evidence that aluminum-coated particles phagocytozed in the injected muscle and its draining lymph nodes can disseminate within phagocytes throughout the body and slowly accumulate in the brain further suggested that alum safety should be evaluated in the long term. However, lack of specific staining makes difficult the assessment of low quantities of bona fide alum adjuvant particles in tissues.
METHODS:
We explored the feasibility of using fluorescent functionalized nanodiamonds (mfNDs) as a permanent label of alum (Alhydrogel(®)). mfNDs have a specific and perfectly photostable fluorescence based on the presence within the diamond lattice of nitrogen-vacancy centers (NV centers). As the NV center does not bleach, it allows the microspectrometric detection of mfNDs at very low levels and in the long-term. We thus developed fluorescent nanodiamonds functionalized by hyperbranched polyglycerol (mfNDs) allowing good coupling and stability of alum:mfNDs (AluDia) complexes. Specificities of AluDia complexes were comparable to the whole reference vaccine (anti-hepatitis B vaccine) in terms of particle size and zeta potential.
RESULTS:
In vivo, AluDia injection was followed by prompt phagocytosis and AluDia particles remained easily detectable by the specific signal of the fND particles in the injected muscle, draining lymph nodes, spleen, liver and brain. In vitro, mfNDs had low toxicity on THP-1 cells and AluDia showed cell toxicity similar to alum alone. Expectedly, AluDia elicited autophagy, and allowed highly specific detection of small amounts of alum in autophagosomes.
CONCLUSIONS:
The fluorescent nanodiamond technology is able to overcome the limitations of previously used organic fluorophores, thus appearing as a choice methodology for studying distribution, persistence and long-term neurotoxicity of alum adjuvants and beyond of other types of nanoparticles.
1 Corinthians 15 Authorized (King James) Version (AKJV)
1 Moreover, brethren, I declare unto you the gospel which I preached unto you, which also ye have received, and wherein ye stand;
2 by which also ye are saved, if ye keep in memory what I preached unto you, unless ye have believed in vain.
3 For I delivered unto you first of all that which I also received, how that Christ died for our sins according to the scriptures;
4 and that he was buried, and that he rose again the third day according to the scriptures:
Hebrews 6 Authorized (King James) Version (AKJV)
1 Therefore leaving the principles of the doctrine of Christ, let us go on unto perfection; not laying again the foundation of repentance from dead works, and of faith toward God,
2 of the doctrine of baptisms, and of laying on of hands, and of resurrection of the dead, and of eternal judgment.
3 And this will we do, if God permit.
4 For it is impossible for those who were once enlightened, and have tasted of the heavenly gift, and were made partakers of the Holy Ghost,
5 and have tasted the good word of God, and the powers of the world to come,
6 if they shall fall away, to renew them again unto repentance; seeing they crucify to themselves the Son of God afresh, and put him to an open shame.
7 For the earth which drinketh in the rain that cometh oft upon it, and bringeth forth herbs meet for them by whom it is dressed, receiveth blessing from God:
8 but that which beareth thorns and briers is rejected, and is nigh unto cursing; whose end is to be burned.
1 Who hath believed our report? and to whom is the arm of the Lord revealed?
2 For he shall grow up before him as a tender plant,and as a root out of a dry ground:he hath no form nor comeliness;and when we shall see him,there is no beauty that we should desire him.
3 He is despised and rejected of men;a man of sorrows, and acquainted with grief:and we hid as it were our faces from him;he was despised, and we esteemed him not.
4 Surely he hath borne our griefs,and carried our sorrows:yet we did esteem him stricken,smitten of God, and afflicted.
5 But he was wounded for our transgressions,he was bruised for our iniquities:the chastisement of our peace was upon him;and with his stripes we are healed.
6 All we like sheep have gone astray;we have turned every one to his own way;and the Lord hath laid on him the iniquity of us all.
7 He was oppressed, and he was afflicted,yet he opened not his mouth:he is brought as a lamb to the slaughter,and as a sheep before her shearers is dumb,so he openeth not his mouth.
8 He was taken from prison and from judgment:and who shall declare his generation? for he was cut off out of the land of the living:for the transgression of my people was he stricken.
9 And he made his grave with the wicked,and with the rich in his death;because he had done no violence,neither was any deceit in his mouth.
10 Yet it pleased the Lord to bruise him;he hath put him to grief:when thou shalt make his soul an offering for sin,he shall see his seed, he shall prolong his days,and the pleasure of the Lord shall prosper in his hand.
11 He shall see of the travail of his soul, and shall be satisfied:by his knowledge shall my righteous servant justify many;for he shall bear their iniquities.
12 Therefore will I divide him a portion with the great,and he shall divide the spoil with the strong;because he hath poured out his soul unto death:and he was numbered with the transgressors;and he bare the sin of many,and made intercession for the transgressors.